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Letter to the Editor
I have read the article by Evans and colleagues published in the JACC -Heart Failure with a great interest (1) . The authors conducted a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events from 16 prospective studies. The results in this study suggest that serum high-sensitivity cardiac Troponin is strongly associated with the risk for incident heart failure beyond conventional risk factors. Certainly, Evans et al. have conducted a very valuable and exciting study. However, the authors mentioned that they were not able to perform a quantitative meta-analysis of the C index data in this study because some studies did not report confidence intervals (CI) for C indexes and their changes. Could the authors calculate a quantitative meta-analysis of the C index only using fully reported studies? This would provide a clearer view that many readers might be interested. The authors demonstrated that in people without baseline cardiovascular disease, NT-proBNP levels strongly predicted first-onset heart failure that could be used to integrate heart failure into primary prevention of cardiovascular diseases. Could Evans et al. do a further analysis to compare the performance of NT-proBNP or BNP levels and high-sensitivity cardiac Troponin as well as other biomarkers such as CRP if it is possible?
